Company: STAA
Filing Date: 2025-09-24
Form Type: DFAN14A
Source: 0001213900-25-091197
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-09-24
Form: DFAN14A
Chunk 2
---
 of STAAR
Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) today announced that it has filed a definitive proxy
statement and GREEN proxy card with the U.S. Securities and Exchange Commission (the “SEC”) and sent a letter to its
fellow stockholders in connection with its opposition to the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE:
ALC) on the terms announced on August 5, 2025 (the “Proposed Merger”).

The full text of Broadwood’s letter is below.

<div align='center'>* * *</div>

September 24, 2025

Dear Fellow STAAR Surgical Stockholders,

Broadwood Partners, L.P. and its affiliates (collectively,
“Broadwood,” “we,” “us,” or “our”) have been committed investors in, and strong supporters
of STAAR Surgical Company (“STAAR” or the “Company”) for more than thirty years. We provided needed capital to
the Company on various occasions and purchased a substantial number of additional shares over time in the public markets, including as
recently as a few months ago. Today, we beneficially own approximately 27.5% of STAAR’s outstanding shares, making us the Company’s
largest stockholder by a significant margin.

We initially invested in STAAR, and have added
to our position over time, because we believe STAAR’s EVO Implantable Collamer® Lens technology is ideally positioned to emerge
as the superior choice for surgeons and patients in the global refractive surgery market. Leading ophthalmologists increasingly share
this opinion, as has been illustrated by published studies around the world and presentations at recent major ophthalmology conferences.
We believe STAAR can capture this multi-billion-dollar market opportunity and drive sustainable, profitable growth and long-term value.

Inopportune Timing

Admittedly, STAAR’s path as a public company
has not always been smooth. Since 2022, macroeconomic headwinds affected the growth of the refractive surgery market. Additionally, under
prior leadership, STAAR executed poorly in China, causing STAAR’s revenue to temporarily decline and profits to evaporate. However,
as STAAR and some of its customers have recently acknowledged, these issues are abating. The Company is now forecasting a return to growth
and profitability.

Given the foreseeable turnaround in STAAR’s
prospects, we are disappointed that STAAR’s Board of Directors